Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.

ABSTRACT:

Background

The tumor mutational burden (TMB) is a promising biomarker for immune checkpoint inhibitor (ICI). However, its relationships with clinical parameters have not been fully explored. We aimed to assess potential factors including age, microsatellite instability (MSI) state, tumor types, and gene mutations that might influence TMB value through analyzing 1,504 tissue samples and 496 blood samples from cancer patients.

Methods

The TMB value of individual samples was calculated by whole-exome sequencing (WES) analysis and major cancer-related gene mutations were evaluated using panel sequencing. MSI was detected with MSI analysis system.

Results

The results showed that for blood samples, compared to age 1 (age ≤56 years old) or age 2 (56< age <68 years old) group

SUBMITTER: Li L 

PROVIDER: S-EPMC8908122 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature